Albendazole for lymphatic filariasis.

Area of Science:

• Tropical medicine
• Parasitology
• Public health

Background:

• Mass treatment with albendazole and other antifilarial drugs is crucial for global lymphatic filariasis elimination programs.
• Evidence on albendazole's efficacy in treating lymphatic filariasis and its parasite is being evaluated.

Purpose of the Study:

• To systematically review the effects of albendazole, alone or in combination, for lymphatic filariasis treatment and community control.
• To assess albendazole's impact on microfilariae prevalence and density.

Main Methods:

• Conducted a systematic search of multiple databases and contacted researchers for relevant randomized and quasi-randomized controlled trials.
• Included trials evaluating albendazole alone or combined with antifilarial drugs for lymphatic filariasis.
• Independently assessed trial eligibility, quality, and extracted data.

Main Results:

• Albendazole showed no significant effect on microfilariae prevalence compared to placebo, but one trial indicated lower density.
• Albendazole was slightly less effective than ivermectin and showed minimal difference compared to diethylcarbamazine (DEC).
• Albendazole combined with ivermectin demonstrated a statistically significant reduction in microfilariae prevalence and density in some trials.

Conclusions:

• Insufficient evidence exists to confirm albendazole's superior efficacy when co-administered with DEC or ivermectin for clearing microfilariae or adult worms.
• Albendazole combined with ivermectin may have a minor, inconsistent effect on microfilaraemia.
• Further rigorous research is essential to determine albendazole's effectiveness against filarial parasites, alone and in combination therapies.